{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06444360",
            "orgStudyIdInfo": {
                "id": "ATN170"
            },
            "organization": {
                "fullName": "Westat",
                "class": "OTHER"
            },
            "briefTitle": "Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Young Gay/Bisexual Minority Men (IMPACT)",
            "officialTitle": "Hybrid Type 2 Effectiveness-Implementation Trial of Status Neutral, Integrated Behavioral Activation and Risk Reduction Intervention for Stimulant Use Among Sexually Active Young Gay/Bisexual Sexual Minority Men (Project IMPACT)",
            "acronym": "IMPACT",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "behavioral-activation-and-risk-reduction-for-stimulant-use-among-sexually-active-young-gay-bisexual-minority-men-impact"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-22",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-30",
            "studyFirstSubmitQcDate": "2024-06-04",
            "studyFirstPostDateStruct": {
                "date": "2024-06-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Westat",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
                    "class": "NIH"
                },
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                },
                {
                    "name": "National Institute of Mental Health (NIMH)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The use of behavioral intervention to reduce stimulant use and concurrent HIV sexual transmission risk",
            "detailedDescription": "IMPACT is a Human Immunodeficiency Virus (HIV) status-neutral, behavioral intervention to reduce stimulant use and concurrent HIV sexual transmission risk. This study will evaluate the effectiveness of IMPACT and determine feasibility of implementing IMPACT across various settings for translation into real-world practice using a hybrid effectiveness-implementation design.\n\nThe IMPACT intervention includes 10 sessions: 2 intervention sessions of HIV risk reduction (RR), 1 session focused on orienting and rationale of behavioral activation (BA), 6 sessions integrating BA and RR-including pre-exposure prophylaxis (PrEP) or antiretroviral therapy (ART) and HIV care-and 1 final session on relapse prevention.\n\nThe enhanced Standard of Care (eSOC) group includes two HIV RR intervention sessions."
        },
        "conditionsModule": {
            "conditions": [
                "HIV"
            ],
            "keywords": [
                "HIV Sexual Transmission Risk",
                "Behavioral Activation",
                "Risk Reduction Intervention",
                "Stimulant Use"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "The study is a two-arm, multisite, and multiformat randomized controlled trial (RCT). IMPACT is a status-neutral intervention that uses behavioral activation (BA)-an evidence-based, cognitive behavior therapy-as a treatment for stimulant use and sexual risk reduction (RR) counseling for young gay/bisexual sexual minority men.\n\nThe IMPACT intervention includes 10 sessions: 2 intervention sessions of HIV RR, 1 session focused on orienting and rationale of BA, 6 sessions integrating BA and RR-including pre-exposure prophylaxis (PrEP) or antiretroviral therapy (ART) and HIV care-and 1 final session on relapse prevention.\n\nThe enhanced Standard of Care (eSOC) group includes two HIV risk reduction intervention sessions.",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 360,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "IMPACT Group",
                    "type": "EXPERIMENTAL",
                    "description": "A multifaceted training and implementation strategy across sites and formats will be used. Participants who report stimulant use in the context of condomless anal sex (CAS), will be randomized using a 2:1 allocation ratio with two-thirds being allocated to the IMPACT intervention. The participants in this arm participate in 10 sessions (approximately 50 minutes each) delivered over the course of approximately 10 weeks.",
                    "interventionNames": [
                        "Behavioral: IMPACT"
                    ]
                },
                {
                    "label": "Enhanced Standard of Care (eSOC) Control Group",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "The comparison arm will receive the same 2 HIV sexual risk reduction (RR) intervention sessions and referrals to substance use and mental health treatment, per SOC.",
                    "interventionNames": [
                        "Behavioral: eSOC"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "IMPACT",
                    "description": "The IMPACT intervention consists of 10 sessions: 2 sessions focused on HIV acquisition/transmission risk reduction (RR), 1 session focused on orienting and rationale to behavioral activation (BA), 6 sessions integrating BA and HIV RR counseling (including PrEP or ART and HIV care), and 1 final session on strategies for slip-ups and recurrence management.",
                    "armGroupLabels": [
                        "IMPACT Group"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "eSOC",
                    "description": "The eSOC group consists of 2 sessions focused on HIV acquisition/transmission risk reduction (RR).",
                    "armGroupLabels": [
                        "Enhanced Standard of Care (eSOC) Control Group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Distinct acts of condomless anal sex (CAS) without the protection of PrEP or viral suppression.",
                    "description": "The number of times participants report engaging in a CAS act without the protection of prevention-effective PrEP (for those not living with HIV) or viral suppression (for those living with HIV).",
                    "timeFrame": "Participants will recall and report acts of CAS and medication adherence for the 30 days prior to each of 4 visits: Baseline, Month 4, Month 8 and Month 12 after enrollment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Days of stimulant use",
                    "description": "The number of days participants report having used stimulants",
                    "timeFrame": "Participants will recall and report the number of days they used stimulants out of the 30 days prior to each of 4 visits: Baseline, Month 4, Month 8 and Month 12 after enrollment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 16-24 years, inclusive, at enrollment\n* Assigned male at birth\n* Identifies as a cisgender boy or man\n* Self-reports condomless anal sex (CAS) with another boy/man-receptive or insertive-while using stimulants (1 hour prior to, or during sex) within the last 4 months; stimulants is defined as crystal methamphetamine, cocaine, and MDMA (e.g., ecstasy, molly)\n* Willing and able to provide written informed consent for study participation\n\nIn addition, virtual participants must meet all the below criteria:\n\n* Access to a computer/smartphone/tablet that can use video chat (e.g., Zoom or Google Meet)\n* Provide a mailing address where they can receive a package\n* Access to stable internet that they can use for more than 2 hours at a time\n* Have a private place (where no one else can see or hear) where they can complete visits online\n* Reside within the continental U.S.\n\nExclusion Criteria:\n\n* Unable to provide informed consent due to severe mental or physical illness\n* Concurrent enrollment in another HIV prevention or treatment study (enrollment in a substance treatment program is acceptable\n* Non-English-speaking\n* Is currently incarcerated or pending incarceration\n* Any other medical condition, medical/behavioral intervention, or other condition that, in the opinion of the Site Consortium Project Lead or designee, could interfere with the safety of participants or staff, adherence to study procedures, or compromise interpretation of study results",
            "healthyVolunteers": true,
            "sex": "MALE",
            "genderBased": true,
            "genderDescription": "Assigned male at birth",
            "minimumAge": "16 Years",
            "maximumAge": "24 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Erin Ricketts",
                    "role": "CONTACT",
                    "phone": "240-453-2786",
                    "email": "erinricketts@westat.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Katie Biello, PhD, MPH",
                    "affiliation": "Brown University",
                    "role": "STUDY_CHAIR"
                },
                {
                    "name": "Matthew Mimiaga, ScD, MPH",
                    "affiliation": "University of California, Los Angeles",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, Los Angeles",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90025",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Eun Kwak",
                            "role": "CONTACT",
                            "phone": "310-825-3094",
                            "email": "ekwak@ph.ucla.edu"
                        },
                        {
                            "name": "Matthew Mimiaga, ScD, MPH",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Children's Hospital Los Angeles",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90027",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Julie McAvoy-Banerjea",
                            "role": "CONTACT",
                            "phone": "323-361-5023",
                            "email": "jmcavoy@chla.usc.edu"
                        },
                        {
                            "name": "Marvin Belzer, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Emory Atlanta Adolescent Consortium",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sierra Jordan-Thompson",
                            "role": "CONTACT",
                            "phone": "404-616-9839",
                            "email": "sierra.jordan@emory.edu"
                        },
                        {
                            "name": "Andres Camacho-Gonzalez, MD, MsC",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "University Illinois Chicago",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Raymond McPherson",
                            "role": "CONTACT",
                            "phone": "312-572-4531",
                            "email": "raymondm@uic.edu"
                        },
                        {
                            "name": "Kelly Bojan, DNP, APRN",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Tulane University",
                    "city": "New Orleans",
                    "state": "Louisiana",
                    "zip": "70112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sean Sylve",
                            "role": "CONTACT",
                            "phone": "504-988-5348",
                            "email": "ssylve2@tulane.edu"
                        },
                        {
                            "name": "Tina Simpson, MD, MPH",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.95465,
                        "lon": -90.07507
                    }
                },
                {
                    "facility": "The Fenway Institute",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Be the Change",
                            "role": "CONTACT",
                            "phone": "617-927-6309",
                            "email": "bethechange@fenwayhealth.org"
                        },
                        {
                            "name": "Ken Mayer, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Brown University",
                    "city": "Providence",
                    "state": "Rhode Island",
                    "zip": "02912",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "IMPACT 170",
                            "role": "CONTACT",
                            "phone": "401-863-3292",
                            "email": "impact170@brown.edu"
                        },
                        {
                            "name": "Katie Biello, PhD, MPH",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.82399,
                        "lon": -71.41283
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4029",
                    "name": "Central Nervous System Stimulants",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "CNSSti",
                    "name": "Central Nervous System Stimulants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}